Literature DB >> 20602727

Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder.

Akiko Okuda1, Tatsuyo Suzuki, Taro Kishi, Yoshio Yamanouchi, Kazunori Umeda, Hiroshi Haitoh, Shuji Hashimoto, Norio Ozaki, Nakao Iwata.   

Abstract

AIMS: The aim of this study was to analyze the relation between treatment response and the duration of untreated illness (DUI) in 133 outpatients with the first major depressive disorder (MDD) episode.
METHODS: A logistic regression was performed with DUI, sex, age at onset, and score for 17 items on the Hamilton Depression Rating Scale at the time of start of fluvoxamine treatment as the explanatory variables, and the response and the remission as the outcome variables.
RESULTS: Regression analysis showed significant association between the response and DUI (P < 0.0001), and between the remission and DUI (P < 0.0001), respectively. The remission rate gradually decreased with longer DUI.
CONCLUSION: Early treatment of first depressive episodes is important because a shorter DUI implied better remission outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20602727     DOI: 10.1111/j.1440-1819.2010.02091.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  16 in total

1.  Epidemiology of chronic and nonchronic major depressive disorder: results from the national epidemiologic survey on alcohol and related conditions.

Authors:  Jose M Rubio; John C Markowitz; Analucía Alegría; Gabriela Pérez-Fuentes; Shang-Min Liu; Keng-Han Lin; Carlos Blanco
Journal:  Depress Anxiety       Date:  2011-08       Impact factor: 6.505

2.  Sustained Molecular Pathology Across Episodes and Remission in Major Depressive Disorder.

Authors:  Enzo Scifo; Mohan Pabba; Fenika Kapadia; Tianzhou Ma; David A Lewis; George C Tseng; Etienne Sibille
Journal:  Biol Psychiatry       Date:  2017-08-18       Impact factor: 13.382

3.  Early cognitive behavioral therapy for depression after cardiac surgery.

Authors:  Lynn V Doering; Belinda Chen; Rebecca Cross Bodán; Marise C Magsarili; Adey Nyamathi; Michael R Irwin
Journal:  J Cardiovasc Nurs       Date:  2013 Jul-Aug       Impact factor: 2.083

4.  Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.

Authors:  Stuart A Montgomery; Carl P Gommoll; Changzheng Chen; William M Greenberg
Journal:  CNS Spectr       Date:  2014-06-05       Impact factor: 3.790

5.  Potential predictors of delay in initial treatment contact after the first onset of depression in Japan: a clinical sample study.

Authors:  Yoshiyo Oguchi; Atsuo Nakagawa; Mitsuhiro Sado; Dai Mitsuda; Yuko Nakagawa; Noriko Kato; Sayuri Takechi; Mitsunori Hiyama; Masaru Mimura
Journal:  Int J Ment Health Syst       Date:  2014-12-05

6.  Factors associated with unwillingness to seek professional help for depression: a web-based survey.

Authors:  Eisho Yoshikawa; Toshiatsu Taniguchi; Nanako Nakamura-Taira; Shin Ishiguro; Hiromichi Matsumura
Journal:  BMC Res Notes       Date:  2017-12-04

7.  Young people with depression and their experience accessing an enhanced primary care service for youth with emerging mental health problems: a qualitative study.

Authors:  Terence V McCann; Dan I Lubman
Journal:  BMC Psychiatry       Date:  2012-08-01       Impact factor: 3.630

8.  Combination use of Beck Depression Inventory and two-question case-finding instrument as a screening tool for depression in the workplace.

Authors:  Yasunori Adachi; Branko Aleksic; Ryoko Nobata; Tatsuyo Suzuki; Keizo Yoshida; Yuichiro Ono; Norio Ozaki
Journal:  BMJ Open       Date:  2012-05-07       Impact factor: 2.692

9.  The impact of the duration of an untreated episode on improvement of depression and somatic symptoms.

Authors:  Ching-I Hung; Nan-Wen Yu; Chia-Yih Liu; Kuan-Yi Wu; Ching-Hui Yang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-27       Impact factor: 2.570

Review 10.  Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient.

Authors:  Oloruntoba J Oluboka; Martin A Katzman; Jeffrey Habert; Diane McIntosh; Glenda M MacQueen; Roumen V Milev; Roger S McIntyre; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.